Shenzhen Salubris Pharmaceuticals (SHE:002294) has received approval from China's National Medical Products Administration for the clinical trial of its SAL012 injection.
The drug will be tested as a treatment for advanced solid tumors, according to a Shenzhen bourse filing on Saturday.